Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)

Talimogene laherparepvec (T-VEC) is an intralesional oncolytic viral therapy for the treatment of recurrent, unresectable cutaneous, subcutaneous, and nodal melanoma. It is thought to work through direct tumor oncolysis and by eliciting a tumor-specific systemic immune response. Immune-related adver...

Full description

Bibliographic Details
Main Authors:	Jennifer Gardner, Teresa Hyun, Gideon Steinbach, John Thompson
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2018-07-01
Series:	Journal of Immunotherapy and Precision Oncology
Subjects:	colitis immune-related adverse event immunotherapy melanoma talimogene laherparepvec
Online Access:	https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_3_18

Similar Items

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma
by: Goar Egoryan, et al.
Published: (2024-12-01)

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report
by: Saurabh D. Chitnis, et al.
Published: (2024-05-01)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
by: James Sun, et al.
Published: (2020-07-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
by: Jonathan T. Blackmon, et al.
Published: (2017-05-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
by: Yifan Hong, et al.
Published: (2024-12-01)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus <i>Talimogene Laherparepvec</i> with Small Molecule Inhibitors
by: Stavros Sotiriadis, et al.
Published: (2024-05-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
by: Howard L. Kaufman, et al.
Published: (2017-09-01)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
by: Kleemann J, et al.
Published: (2021-07-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
by: Matthew C Perez, et al.
Published: (2019-06-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
by: Erika Richtig, et al.
Published: (2021-02-01)

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
by: Ibrahim Ragab Eissa, et al.
Published: (2017-07-01)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published: (2021-10-01)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
by: Ann W. Silk, et al.
Published: (2016-09-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Clinical characterization of colitis arising from anti-PD-1 based therapy
by: Daniel Y Wang, et al.
Published: (2019-01-01)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
by: Jennifer Gardner, et al.
Published: (2022-10-01)

Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis
by: Yoki Furuta, et al.
Published: (2020-02-01)

Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients
by: Hyun Ju Kim, et al.
Published: (2019-09-01)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
by: Malidi Ahamadi, et al.
Published: (2023-02-01)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
by: Alisa Lepper, et al.
Published: (2023-12-01)

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
by: Dean A Fergusson, et al.
Published: (2019-12-01)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
by: Umang Swami, et al.
Published: (2019-01-01)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
by: Lukas Kraehenbuehl, et al.
Published: (2023-06-01)